HK1186736A1 - -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽 - Google Patents

-{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽

Info

Publication number
HK1186736A1
HK1186736A1 HK13114246.8A HK13114246A HK1186736A1 HK 1186736 A1 HK1186736 A1 HK 1186736A1 HK 13114246 A HK13114246 A HK 13114246A HK 1186736 A1 HK1186736 A1 HK 1186736A1
Authority
HK
Hong Kong
Prior art keywords
benzenesulfonyl
pyrrol
pyrazol
phenyl
amino
Prior art date
Application number
HK13114246.8A
Other languages
English (en)
Inventor
于爾根．沃爾茲
馬丁．費斯
羅爾夫-彼得．胡梅爾
馬蒂亞斯．穆勒
托馬斯．梅艾爾
波恩德．穆勒
Original Assignee
股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 股份公司 filed Critical 股份公司
Publication of HK1186736A1 publication Critical patent/HK1186736A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
HK13114246.8A 2008-03-12 2013-12-24 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽 HK1186736A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08004568A EP2100882A1 (en) 2008-03-12 2008-03-12 (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts

Publications (1)

Publication Number Publication Date
HK1186736A1 true HK1186736A1 (zh) 2014-04-17

Family

ID=39322749

Family Applications (3)

Application Number Title Priority Date Filing Date
HK13114246.8A HK1186736A1 (zh) 2008-03-12 2013-12-24 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽
HK15108828.4A HK1208219A1 (zh) 2008-03-12 2015-09-10 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽
HK18115376.2A HK1256310A1 (zh) 2008-03-12 2018-11-30 N-磺酰基吡咯衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15108828.4A HK1208219A1 (zh) 2008-03-12 2015-09-10 -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽
HK18115376.2A HK1256310A1 (zh) 2008-03-12 2018-11-30 N-磺酰基吡咯衍生物

Country Status (16)

Country Link
US (1) US8557858B2 (zh)
EP (2) EP2100882A1 (zh)
JP (2) JP2011513466A (zh)
KR (1) KR101657718B1 (zh)
CN (5) CN108101890A (zh)
AU (1) AU2009224710B2 (zh)
BR (1) BRPI0908917A2 (zh)
CA (1) CA2719071C (zh)
EA (1) EA017533B1 (zh)
HK (3) HK1186736A1 (zh)
IL (1) IL207994A (zh)
MX (1) MX2010010014A (zh)
NZ (1) NZ587823A (zh)
UA (1) UA106351C2 (zh)
WO (1) WO2009112522A1 (zh)
ZA (1) ZA201006523B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508464B8 (pt) * 2004-03-11 2021-05-25 Altana Pharma Ag sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
DK2680694T3 (en) 2011-02-28 2019-03-25 Biomarin Pharm Inc HISTONDEACETYLASE INHIBITORS
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN102526714B (zh) * 2011-08-24 2013-12-25 贵州神奇集团控股有限公司 治疗肿瘤的药物组合物及其制备方法
CN102716465B (zh) * 2012-06-18 2014-01-15 贵州金桥药业有限公司 治疗肿瘤的药物组合物及其制备方法
CA2903490C (en) 2013-03-15 2021-04-13 Biomarin Pharmaceutical Inc. Hdac inhibitors
WO2017060524A1 (en) * 2015-10-09 2017-04-13 4Sc Ag (e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide for the treatment of latent viral infections
TW201919614A (zh) 2017-09-08 2019-06-01 德商４Ｓｃ製藥公司 Hdac抑制劑與免疫檢查點調節劑組合用於癌症治療
AU2019246140A1 (en) 2018-03-26 2020-09-17 4Sc Ag Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
TW202012395A (zh) * 2018-04-14 2020-04-01 德商４Ｓｃ製藥公司 用於治療癌症的包含組蛋白去乙醯酶（hdac）抑制劑和tlr7 激動劑和/或tlr8 激動劑的藥物組合產品
KR20200143452A (ko) 2018-04-17 2020-12-23 4에스체 악티엔게젤샤프트 암 치료를 위한 hdac 억제제, lag-3 억제제 및 pd-1 억제제 또는 pd-l1 억제제를 포함하는 배합물
TW202114659A (zh) 2019-10-02 2021-04-16 德商４Ｓｃ製藥公司 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合
CN111973590A (zh) * 2020-07-06 2020-11-24 江苏省人民医院（南京医科大学第一附属医院） 新型hdac抑制剂laq824在治疗弥漫大b细胞淋巴瘤药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
EP0828718A1 (en) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
US20030118078A1 (en) * 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
BRPI0508464B8 (pt) * 2004-03-11 2021-05-25 Altana Pharma Ag sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
SI1861365T1 (sl) 2005-03-15 2009-12-31 4Sc Ag N-sulfonilpiroli in njihova uporaba kot inhibitorji histon deacetilaze
AU2006232773B2 (en) * 2005-04-07 2012-04-12 4Sc Ag Sulfonylpyrroles as histone deacetylase inhibitors
ES2381962T3 (es) * 2005-09-21 2012-06-04 4Sc Ag Nuevos sulfonilpirroles como inhibidores de las HDAC
JP5305909B2 (ja) * 2005-09-21 2013-10-02 フォーエスシー アクチエンゲゼルシャフト ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール塩酸塩
EP2100878A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors

Also Published As

Publication number Publication date
IL207994A (en) 2015-10-29
CN101970411A (zh) 2011-02-09
WO2009112522A1 (en) 2009-09-17
US8557858B2 (en) 2013-10-15
KR101657718B1 (ko) 2016-09-19
JP2011513466A (ja) 2011-04-28
BRPI0908917A2 (pt) 2021-04-13
CN103360371A (zh) 2013-10-23
HK1208219A1 (zh) 2016-02-26
MX2010010014A (es) 2011-04-05
CN108101890A (zh) 2018-06-01
CN104803988A (zh) 2015-07-29
NZ587823A (en) 2012-05-25
JP5952328B2 (ja) 2016-07-13
KR20100133422A (ko) 2010-12-21
CN103360371B (zh) 2015-03-25
US20110086897A1 (en) 2011-04-14
EP2100882A1 (en) 2009-09-16
HK1256310A1 (zh) 2019-09-20
JP2014132027A (ja) 2014-07-17
CA2719071C (en) 2016-07-12
AU2009224710A1 (en) 2009-09-17
UA106351C2 (en) 2014-08-26
CA2719071A1 (en) 2009-09-17
EA017533B1 (ru) 2013-01-30
IL207994A0 (en) 2010-12-30
EA201001269A1 (ru) 2011-06-30
EP2262775A1 (en) 2010-12-22
ZA201006523B (en) 2011-09-28
AU2009224710B2 (en) 2013-05-02
CN110183425A (zh) 2019-08-30

Similar Documents

Publication Publication Date Title
HK1208219A1 (zh) -{ }- -氨基-苯基 -{ -甲基- -吡唑- -基 -苯磺酰基 -吡咯- -基}-丙烯酰胺甲苯磺酸鹽
IL209980A0 (en) Sulfonamide compounds or salts thereof
IL205742A0 (en) 4-(4-cyano-2-thioaryl)
AU322949S (en) Vibrator
GB0811643D0 (en) New therapeutic agents
GB2476842B (en) Forceps
GB0808711D0 (en) Tissue assessment
BRPI0822849A2 (pt) Aparelho para cirurgia oftalmológica
EP2349266A4 (en) Sulphonamide-containing compounds and their uses
IL208519A0 (en) Substituted sulfonamide derivatives
GB0916755D0 (en) Physiological monitor
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares
ZA201006548B (en) Pyrimidylmethyl sulfonamide compounds
AP2612A (en) Improved herbicidal formulation
GB2446447B (en) Tissue tensiometer
GB0821478D0 (en) Novel skin brightening agents
GB0901480D0 (en) Contrast agents
GB0821135D0 (en) Lanthanide compounds
GB0820674D0 (en) Benzamide compounds
ES1068841Y (es) Armario para terminales de usuario
AU4585P (en) WES05 Westringia fruticosa
GB0800265D0 (en) Tissue monitor
ES1068189Y (es) Cabezal para mochos de fregona
GB0722374D0 (en) Benzamide compounds
GB0815765D0 (en) New therapeutic agents